CAMBRIDGE, Mass., Dec 13, 2011 (GlobeNewswire around COMTEX) –
Pathfinder Cell Therapy, Inc. (“Pathfinder”) (otcqb:PFND), a biotechnology association focused on a diagnosis of diseases characterized by organ-specific dungeon damage, now supposing a swell refurbish on a investigate and expansion activities for a Company’s exclusive Pathfinder Cells (“PCs”). In mixed animal models, Pathfinder has arguable a ability of PCs to kindle a healthy metamorphosis of surrounding shop-worn tissues though a cells being incorporated into a newly generated tissue. These certain rough information support serve expansion of PCs as a intensity diagnosis for several vicious tellurian diseases including diabetes, cardiac ischemia, and renal reperfusion injury.
Pathfinder’s stream RD programs follow 3 tracks: 1) serve exploring animal models to expose a operation of intensity indications for that PCs might be effective; 2) informative a underlying resource by that PCs are means to renovate shop-worn tissues; and 3) laying vicious grounds for securing a arguable and controllable hankie source for PCs and final best practices for preparation, dungeon growth, storage and doing of PCs.
What are Pathfinder Cells?
Pathfinder Cells are a newly identified mammalian dungeon form detected by Pathfinder that have a ability to kindle hankie metamorphosis in a series of opposite organs. PCs are not branch cells and are discernible from dungeon forms being grown by other companies for use in regenerative medicine by dungeon aspect and other markers.
PCs can be found in a series of opposite organs, including a kidney, liver, pancreas, lymph nodes, myometrium, and placenta. Pathfinder has removed PCs from humans and rats, and used cells subsequent from both sources successfully to renovate shop-worn hankie in mice though a PCs being incorporated into a newly generated tissue. This conspicuous materialisation indicates that PCs seem to be “immune privileged,” and therefore might be means to be used between immunologically opposite individuals.
Evaluating Potential Indications for Clinical Development
Pathfinder has done poignant swell in exploring a healing intensity of PCs by a use of animal models. Determining a specific indications for that PCs denote efficiency will assistance brand a suitable indication(s) that should be targeted for tellurian clinical studies.
The association announced formerly that it had demonstrated certain rough formula from animal studies representing vicious tellurian conditions including diabetes, myocardial infarction (cardiac ischemia), and renal reperfusion injury. In a final 12 months, Pathfinder was means to endorse these pivotal commentary in all 3 illness models, demonstrating a extent of intensity indications where PC-based therapy might be efficacious.
In Mar 2011, Pathfinder announced a announcement of constrained rodent information in a peer-reviewed systematic biography Rejuvenation Research. The investigate showed that PCs were effective during regenerating critically shop-worn hankie in a common Streptozotocin (STZ)-induced diabetic rodent model. Ultimately, a information demonstrated that a Company’s singular cell-based therapy was means to totally retreat diabetes in this sold illness indication in mice. The Company is in a routine of scheming manuscripts describing a formula for myocardial infarction and renal reperfusion repairs and skeleton to contention these commentary for intensity announcement in peer-reviewed journals in a nearby future.
In together with these assenting studies, Pathfinder has continued contrast PCs for a intensity diagnosis of other diseases that engage organ-specific dungeon damage. The Company is in a early stages of examining PCs for a diagnosis of vicious prong ischemia in a rodent indication as good as in a rodent indication of osteoarthritis. Preliminary information from these studies have been encouraging.
Exploring Potential Mechanisms of Action
While diagnosis with PCs has shown extended efficiency in animal models, a mechanisms by that PCs kindle metamorphosis of surrounding hankie are not nonetheless entirely understood. PCs seem to furnish microvesicles in vivo, that are expelled by a PCs extracellularly where they can hit and enter surrounding cells. Pathfinder has been examining these microvesicles constructed by both rodent and tellurian PCs, as good as a microRNA contained in those microvesicles. Through these studies, researchers have been successful in identifying a tiny series of withheld molecules, that seem to aim a singular series of pathways. Based on a inlet of these pathways, these commentary are unchanging with a effects seen formerly in animal studies.
While speedy by a swell done to date, Pathfinder’s RD group is stability to impersonate PCs in sequence to improved know a healing mechanisms. A low bargain of how PCs kindle hankie metamorphosis is vicious for conceptualizing cell-based therapies with a intensity to impact a diagnosis of tellurian diseases.
Investigating Controllable Sources and Improved Bioprocessing Systems
Although PCs are in early-stage development, Pathfinder’s ability to source and grow PCs reliably and during an increasing scale will be vicious to a Company’s ability to beget commercially viable PC-based products in a future. This is loyal of any development-stage cell-based therapy and it can be a extensive process. Pathfinder is committed to questioning a many fit and arguable prolongation solutions in sequence to maximize a intensity of PCs.
While PCs have been found in a pancreas, kidney, and other organs, some of these tissues are not straightforwardly accessible from controllable sources. For this reason, choice sources contingency be identified and grown for commercial-scale production. Pathfinder is now questioning PCs removed from tellurian placenta, cord blood, tonsil, and myometrium. The analysis routine starts with hankie collection, and afterwards isolating PCs and flourishing them in culture. Because PCs are some-more formidable to grow than some other mammalian dungeon types, including mesenchymal branch cells, Pathfinder is also questioning a series of technologies that might boost a expansion intensity of PCs underneath laboratory conditions. Once adequate PCs have been generated, their activity contingency be evaluated and arguable by contrast in certified animal models. Pathfinder is now regulating a STZ-induced diabetic rodent indication as a customary anxiety test for these tests.
Once these elements are in place, Pathfinder intends to trigger large-scale good prolongation practices (GMP) prolongation in credentials for toxicology studies and clinical trials. The Company skeleton to yield updates on these skeleton as appropriate.
About Pathfinder Cell Therapy, Inc.
Pathfinder is building a novel cell-based therapy with a intensity to renovate a diagnosis of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific dungeon damage. Leveraging a inner find of Pathfinder Cells, and a exclusive means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new margin in regenerative medicine. PCs are a newly identified mammalian dungeon form benefaction in really low quantities in a accumulation of opposite organs, including a kidney, liver, pancreas, lymph nodes, and other tissues.
Early studies prove that PCs kindle metamorphosis of shop-worn hankie though a cells themselves being incorporated into a new tissue. The cells seem to be “immune privileged,” and their effects are eccentric of a hankie source of PCs. PCs removed from both rodent and tellurian hankie sources have shown efficiency in animal models of diabetes, cardiac ischemia, and renal reperfusion injury.
For some-more information greatfully visit:
www.pathfindercelltherapy.com
FORWARD-LOOKING STATEMENTS
This press recover contains forward-looking statements. You should be wakeful that a tangible formula could differ materially from those contained in a forward-looking statements, that are formed on management’s stream expectations and are theme to a series of risks and uncertainties, including, though not singular to, risks associated to regulatory approvals and a success of Pathfinder’s ongoing and destiny studies, including a success of PCs, and uncertainties relating to a accessibility of collateral to support Pathfinder’s research, expansion and intensity product commercialization activities, and a success of a research, development, regulatory approval, selling and placement skeleton and strategies. These and other risks and uncertainties are identified and described in some-more fact in a Company’s filings with a Securities and Exchange Commission including a decisive substitute matter filed on Jul 26, 2011. The Company undertakes no requirement to publicly refurbish or correct any forward-looking statements.
This news recover was distributed by GlobeNewswire,
www.globenewswire.com
SOURCE: Pathfinder Cell Therapy, Inc.
CONTACT: The Ruth Group
Joshua Drumm (investors) / Victoria Aguiar (media)
(646) 536-7006 / (646) 536-7013
jdrumm@theruthgroup.com / vaguiar@theruthgroup.com
Rick Franklin
CEO, Pathfinder LLC
Rick.Franklin@PathfinderCellTherapy.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Incoming search terms:
![[ Back to EurekAlert! ]](http://farmacred.com/wp-content/plugins/RSSPoster_PRO/cache/ae51c_back2e.gif){kind=small}
Share
